

# Tanya Simuni

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3519214/tanya-simuni-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103  
papers

3,858  
citations

28  
h-index

61  
g-index

110  
ext. papers

5,391  
ext. citations

6.5  
avg, IF

5.15  
L-index

#	Paper	IF	Citations
103	Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.. <i>NeuroImage: Clinical</i> , <b>2022</b> , 34, 103022	5.3	0
102	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 705407	4.1	5
101	New dopaminergic therapies for PD motor complications. <i>Neuropharmacology</i> , <b>2021</b> , 204, 108869	5.5	1
100	Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> ,	7	3
99	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2021</b> , 78, 312-320	17.2	34
98	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 395-404	5.3	7
97	Phase 3 in Focus - Amprelosetine, Theravance Biopharma. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 391-393		
96	Clinical Trial Highlights - Kinase Inhibitors. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 377-390	5.3	
95	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1972-1978	7	1
94	Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1979-1983	7	
93	A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, S27-S34	5.3	8
92	Progress towards therapies for disease modification in Parkinson's disease. <i>Lancet Neurology</i> , <b>2021</b> , 20, 559-572	24.1	13
91	Clinical Trial Highlights - Parkinson's Disease Cognition. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 9-30	5.3	
90	Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 308-320	5.3	6
89	Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 603-612	5.3	13
88	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 83, 115-122	3.6	3
87	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 926-939	27.4	16

86	Seeking progress in disease modification in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 90, 134-141	3.6	4
85	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. <i>Movement Disorders</i> , <b>2021</b> , 36, 2687-2692	7	3
84	The effects of a simulated fMRI environment on voice intensity in individuals with Parkinson's disease hypophonia and older healthy adults. <i>Journal of Communication Disorders</i> , <b>2021</b> , 94, 106149	1.9	1
83	Dopamine transporter imaging predicts clinically-defined $\beta$ synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 201-212	5.3	6
82	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , <b>2020</b> , 88, 574-587	9.4	16
81	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , <b>2020</b> , 35, 833-844	7	18
80	Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. <i>JAMA Neurology</i> , <b>2020</b> , 77, 755-763	17.2	5
79	Role of data measurement characteristics in the accurate detection of Parkinson's disease symptoms using wearable sensors. <i>Journal of NeuroEngineering and Rehabilitation</i> , <b>2020</b> , 17, 52	5.3	18
78	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , <i>The</i> , <b>2020</b> , 19, 71-80	24.1	37
77	Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 574-580	8.1	7
76	Clinical Trial Highlights - Infusion Therapies. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 5-17	5.3	5
75	Evaluation of an Interdisciplinary Screening Program for People With Parkinson Disease and Movement Disorders. <i>Archives of Rehabilitation Research and Clinical Translation</i> , <b>2020</b> , 2, 100067	1.3	1
74	Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up. <i>Movement Disorders</i> , <b>2020</b> , 35, 1550-1557	7	7
73	Infusion Therapies for Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , <b>2020</b> , 20, 44	6.6	6
72	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 80, 127-132	3.6	3
71	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 1816-1830	5.3	10
70	Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 1779-1786	5.3	11
69	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , <b>2020</b> , 35, 1999-2008	7	32

68	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 449-461	5.3	18
67	Clinical Trial Highlights - GLP-1 agonists. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 355-368	5.3	5
66	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 665-679	5.3	8
65	Using Implementation Frameworks to Provide Proactive Physical Therapy for People With Parkinson Disease: Case Report. <i>Physical Therapy</i> , <b>2019</b> , 99, 1644-1655	3.3	7
64	Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. <i>The Lancet Digital Health</i> , <b>2019</b> , 1, e222-e231	14.4	27
63	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 62, 201-209	3.6	9
62	CLINICAL TRIAL HIGHLIGHTS: 1. GENE THERAPY FOR PARKINSON'S, 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA'S ACCORDION PILL, 3. CLINICAL TRIALS RESOURCES. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 251-264	5.3	8
61	Clinical Trial Highlights: Targetting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 5-16	5.3	8
60	Clinical Trial Highlights: Phase III Study in Spotlight. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 3-4	5.3	3
59	Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. <i>Human Brain Mapping</i> , <b>2019</b> , 40, 5094-5107	5.9	30
58	CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 449-465	5.3	3
57	Longitudinal analyses of cerebrospinal fluid $\beta$ synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 1354-1364	7	48
56	Advance care planning in Parkinson's disease: ethical challenges and future directions. <i>Npj Parkinson's Disease</i> , <b>2019</b> , 5, 24	9.7	20
55	Self-reported physical activity levels and clinical progression in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 61, 118-125	3.6	25
54	New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 59, 32-38	3.6	20
53	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , <b>2018</b> , 33, 771-782	7	73
52	The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 51, 9-16	3.6	63
51	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 78-88	5.5	49

50	Altered resting-state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson's disease. <i>Brain and Behavior</i> , <b>2018</b> , 8, e01073	3.4	17
49	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201964	3.7	21
48	High priority publications on Parkinson's disease in 2017. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 8-10	24.1	
47	Wearable sensors for Parkinson's disease: which data are worth collecting for training symptom detection models. <i>Npj Digital Medicine</i> , <b>2018</b> , 1, 64	15.7	72
46	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 1460-1477	5.3	142
45	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , <b>2018</b> , 23, 402-413	1.8	3
44	Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 56, 93-97	3.6	5
43	Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes?. <i>Clinical Imaging</i> , <b>2017</b> , 44, 66-69	2.7	17
42	Laughter is the best medicine: The Second City improvisation as an intervention for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 34, 62-65	3.6	8
41	Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 653-662	5.5	45
40	Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1161-1168	3.8	14
39	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. <i>Experimental Neurology</i> , <b>2017</b> , 298, 202-209	5.7	54
38	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 360-368	5.3	46
37	Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 193-202	5.3	67
36	Altered premotor cortical oscillations during repetitive movement in persons with Parkinson's disease. <i>Behavioural Brain Research</i> , <b>2017</b> , 317, 141-146	3.4	10
35	Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 685-693	5.3	10
34	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175674	3.7	84
33	Motor cortical oscillations are abnormally suppressed during repetitive movement in patients with Parkinson's disease. <i>Clinical Neurophysiology</i> , <b>2016</b> , 127, 664-674	4.3	19

32	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 935-49	14.3	138
31	Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , <b>2016</b> , 16, 34	6.6	17
30	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , <b>2016</b> , 31, 1272-82		305
29	Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 725-33	7	27
28	How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 28, 62-7	3.6	89
27	Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2016</b> , 3, 482-94	5.3	13
26	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 919-27	7	179
25	Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 21-41	5.3	50
24	Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 731-6	5.3	20
23	Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. <i>Movement Disorders</i> , <b>2015</b> , 30, 1371-81	7	53
22	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , <b>2015</b> , 30, 1885-92	7	40
21	Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2015</b> , 2, 371-378	2.2	3
20	Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 773-82	5.3	2
19	Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson's Disease patients assessed using pseudo-continuous arterial spin labeling. <i>PeerJ</i> , <b>2015</b> , 3, e1381	3.1	13
18	The Profile of Long-term Parkinson's Disease Survivors with 20 Years of Disease Duration and Beyond. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 313-9	5.3	16
17	Recognition and treatment of depressive symptoms in Parkinson's disease: the NPF dataset. <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 639-43	5.3	10
16	Is exenatide the next big thing in Parkinson's disease?. <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 345-7	5.3	4
15	Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. <i>JAMA Neurology</i> , <b>2014</b> , 71, 463-9	17.2	204

14	Association of cerebrospinal fluid Aβ <sub>1-42</sub> , T-tau, P-tau <sub>181</sub> , and Synuclein levels with clinical features of drug-naïve patients with early Parkinson disease. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1277-87 <sup>17.2</sup>	252
13	Rankin scale as a potential measure of global disability in early Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , <b>2013</b> , 20, 1200-3	2.2 11
12	Brain donation--what do patients with movement disorders know and how do they feel about it?. <i>Parkinsonism and Related Disorders</i> , <b>2011</b> , 17, 204-7	3.6 18
11	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 629-35	10.9 793
10	Piloting the NPF data-driven quality improvement initiative. <i>Parkinsonism and Related Disorders</i> , <b>2010</b> , 16, 517-21	3.6 31
9	Reply: Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 252-253	7
8	Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. <i>Movement Disorders</i> , <b>2010</b> , 25, 2863-6	7 53
7	Treatment of early Parkinson's disease. Part 1. <i>European Neurology</i> , <b>2009</b> , 61, 193-205	2.1 10
6	Treatment of early Parkinson's disease. Part 2. <i>European Neurology</i> , <b>2009</b> , 61, 206-15	2.1 10
5	Nonmotor manifestations of Parkinson's disease. <i>Annals of Neurology</i> , <b>2008</b> , 64 Suppl 2, S65-80	9.4 121
4	Managing sleep disorders in Parkinson's disease. <i>Aging Health</i> , <b>2007</b> , 3, 49-66	1
3	Somnolence and other sleep disorders in Parkinson's disease: the challenge for the practicing neurologist. <i>Neurologic Clinics</i> , <b>2004</b> , 22, S107-26	4.5 7
2	Nilotinib in Patients with Advanced Parkinson's Disease: A Randomized Phase 2A Study (NILO-PD)	6
1	A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design and baseline data	3